Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX23 Tisotumab vedotin
D11814 Tisotumab vedotin (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Anti-Tissue Factor Antibodies
Tisotumab Vedotin
D11814 Tisotumab vedotin (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11814 Tisotumab vedotin (USAN/INN); Tisotumab vedotin (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
F3 (CD142, TF)
D11814 Tisotumab vedotin (USAN/INN) <US>
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D11814 Tisotumab vedotin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11814
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11814
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11814
